Welcome to our dedicated page for Valneva SE SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE filings document a foreign private issuer focused on prophylactic vaccines for infectious diseases. Its Form 6-K reports and Form 20-F disclosures cover consolidated financial results, product sales, research collaboration revenue, and business updates for marketed vaccines and clinical-stage programs, including Lyme disease, Shigella and chikungunya vaccine activities.
The filing record also includes material-event disclosures incorporated by reference into Form F-3 registration statements. These documents address material agreements, licensing and collaboration arrangements, capital-structure actions, shareholder voting and governance matters, risk factors, and clinical or regulatory updates for Valneva's vaccine candidates and commercial portfolio.
Valneva SE reported that the United Kingdom’s Commission on Human Medicines has updated its recommendations for use of its single-dose chikungunya vaccine IXCHIQ®. The revised prescribing information adds restrictions for people over 60 years of age, for individuals with specified health conditions, and on timing of vaccination before travel.
The UK regulator confirmed that IXCHIQ’s benefit–risk profile remains favorable for people aged 18 to 59 years who are at risk of chikungunya infection and do not have the contraindicated underlying conditions. The update follows a temporary suspension of use in older individuals after serious adverse events were reported mainly in elderly people with significant underlying medical issues during an outbreak vaccination campaign on La Reunion. Valneva states it will continue monitoring post‑marketing safety data and work with authorities on any further adjustments.
Valneva SE has filed a Form 6-K highlighting a new collaboration step with Instituto Butantan in Brazil. The partners are launching a Pilot Vaccination Strategy using Valneva’s single-shot chikungunya vaccine IXCHIQ® across ten Brazilian municipalities selected on epidemiological and operational criteria.
The program, targeting adults aged 18 to 59 years, aims to reach 20% to 40% vaccine coverage in the eligible population. Valneva will supply the initiative by donating up to 500,000 doses of IXCHIQ® through Instituto Butantan to Brazil’s Ministry of Health. This pilot will generate post-marketing, real-world effectiveness and safety data in an endemic setting, building on Brazil’s prior marketing approval of IXCHIQ® for adults in April 2025.
Valneva SE reports that it has voluntarily withdrawn the U.S. biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine IXCHIQ®. This follows the U.S. FDA’s earlier suspension of the IXCHIQ license in August 2025 and a more recent FDA decision to place the IND on clinical hold while it investigates a newly reported serious adverse event (SAE) from outside the U.S.
The SAE involved a younger adult who received three vaccines at the same time, including IXCHIQ; based on available data, the case may be plausibly related to IXCHIQ, but causality has not been determined. Valneva states that no IXCHIQ clinical studies are currently vaccinating participants and that it plans to continue post-marketing clinical activities after further discussions with regulators. The company continues to supply IXCHIQ in territories where it is licensed, including Europe, Canada, the United Kingdom and Brazil, and maintains that the vaccine’s benefit–risk profile remains favorable, particularly for people in endemic and outbreak settings.
Valneva SE filed a Form 6-K to furnish a press release announcing that its management will meet investors during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–14, 2026. The company plans one-on-one meetings with existing shareholders and discussions with other institutional specialist investors.
CEO Thomas Lingelbach and CFO Peter Bühler will present upcoming catalysts from Valneva’s clinical pipeline, including a pivotal data readout for its Lyme disease vaccine in the first half of the year, and will also discuss its commercial vaccine portfolio. Valneva describes itself as a specialty vaccine company with three proprietary travel vaccines on the market and a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a tetravalent Shigella vaccine candidate.
Valneva SE furnished a Form 6-K as a foreign private issuer to provide investors with a press release and unaudited interim condensed consolidated financial statements dated November 26, 2025. These materials, attached as Exhibit 99.1, present the company’s latest results and are incorporated by reference into its existing Form F-3 shelf registration statement.
Valneva SE filed a Form 6-K reporting that it has released its results for the three months ended September 30, 2025. The company furnished a press release and unaudited interim condensed consolidated financial statements as exhibits, providing more detail on its recent quarterly performance.
Most of the information in this Form 6-K, excluding the section titled “Financial Outlook” in the press release, is incorporated by reference into Valneva’s existing Form F-3 registration statement. This means those disclosures can now be used in connection with Valneva’s registered securities offerings in the United States.
Valneva SE entered a senior term loan facility totaling $500.0M, split into a committed $215.0M Tranche A expected to fund around Oct 17, 2025 and up to $285.0M of uncommitted subsequent tranches available with lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement in full; subsequent tranches are reserved for general corporate and working capital needs.
The Term Loans mature five years after each funding date, carry a fixed interest rate of 9.00% per annum with quarterly payments, and include an upfront fee of 2.00% of principal at each funding. Prepayments are permitted but subject to a premium up to 3.00% depending on timing. Separately, the company reconfirmed its Phase 3 Lyme vaccine trial remains on track, with Pfizer targeting BLA and MAA submissions in 2026, VALOR trial outcomes expected in H1 2026, and a contemplated launch in H2 2027 pending approval.
Valneva SE entered a senior term loan facility for an aggregate $500.0M, split into a $215.0M committed Tranche A (expected funded ~Oct 17, 2025) and up to $285.0M of uncommitted subsequent tranches subject to lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement; subsequent tranches are designated for general corporate and working capital including business development and permitted acquisitions. The loans mature five years after each tranche funding and carry a fixed interest rate of 9.00% with quarterly payments. There is a funding fee equal to 2.00% of principal and prepayment premiums of 3.00% if repaid before the third anniversary and 2.00% thereafter. Separately, Valneva reconfirms its Phase 3 Lyme vaccine trial remains on track; Pfizer targets BLA and MAA submissions in 2026 if data are positive, with VALOR outcomes expected in H1 2026 and a potential Pfizer launch in H2 2027.